Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5223 USD | +0.87% | +2.39% | -3.87% |
22/03 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
14/03 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Business Summary
Number of employees: 405
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Zinc Finger Protein
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 111 | 100.0 % | 176 | 100.0 % | +58.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 01/16/01 |
Director of Finance/CFO | 46 | 01/19/01 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Phillip Ramsey
CTO | Chief Tech/Sci/R&D Officer | - | - |
Louise Wilkie
IRC | Investor Relations Contact | - | 01/20/01 |
Amy Pooler
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 01/19/01 | |
Scott Willoughby
LAW | General Counsel | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 15/22/15 |
James Meyers
BRD | Director/Board Member | 58 | 22/19/22 |
H. Parker
CHM | Chairman | 68 | 19/14/19 |
Kenneth Hillan
BRD | Director/Board Member | 63 | 11/20/11 |
Robert Carey
BRD | Director/Board Member | 65 | 01/16/01 |
Karen Smith
BRD | Director/Board Member | 56 | 28/18/28 |
Alexander Macrae
CEO | Chief Executive Officer | 61 | 01/16/01 |
John Markels
BRD | Director/Board Member | 58 | 11/20/11 |
Courtney Beers
BRD | Director/Board Member | 54 | 15/22/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 207,495,609 | 191,497,330 ( 92.29 %) | 0 | 92.29 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.87% | 108M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.46% | 22.18B | |
-16.67% | 21.2B | |
-8.58% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- SGMO Stock
- Company Sangamo Therapeutics, Inc.